Aliases & Classifications for Syncope

MalaCards integrated aliases for Syncope:

Name: Syncope 53 29 6

Summaries for Syncope

NINDS : 53 Syncope is a medical term used to describe a temporary loss of consciousness due to the sudden decline of blood flow to the brain. Syncope is commonly called fainting or “passing out.” If an individual is about to faint, he or she will feel dizzy, lightheaded, or nauseous and their field of vision may “white out” or “black out.”  The skin may be cold and clammy.  The person drops to the floor as he or she loses consciousness.  After fainting, an individual may be unconscious for a minute or two, but will revive and slowly return to normal.  Syncope can occur in otherwise healthy people and affects all age groups, but occurs more often in the elderly.  There are several types of syncope.  Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing.  Carotid sinus syncope happens because of constriction of the carotid artery in the neck and can occur after turning the head, while shaving, or when wearing a tight collar.  Situational syncope happens during urination, defecation, coughing, or as a result of gastrointestinal stimulation.  Syncope can also be a symptom of heart disease or abnormalities that create an uneven heart rate or rhythm that temporarily affect blood volume and its distribution in the body.  Syncope isn’t normally a primary sign of a neurological disorder, but it may indicate an increased risk for neurologic disorders such as Parkinson’s disease, postural orthostatic tachycardia syndrome (POTS), diabetic neuropathy, and other types of neuropathy.  Certain classes of drugs are associated with an increased risk of syncope, including diuretics, calcium antagonists, ACE inhibitors, nitrates, antipsychotics, antihistamines, levodopa, narcotics, and alcohol.

MalaCards based summary : Syncope is related to atrial standstill and left bundle branch hemiblock. An important gene associated with Syncope is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are Transmission across Chemical Synapses and cGMP-PKG signaling pathway. The drugs Dopamine and Fludrocortisone have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and brain, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 74 Syncope, also known as fainting, is a loss of consciousness and muscle strength characterized by a fast... more...

Related Diseases for Syncope

Diseases related to Syncope via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 atrial standstill 10.2 SCN5A NPPA
2 left bundle branch hemiblock 10.1 SCN5A RYR2
3 arrhythmogenic right ventricular dysplasia, familial, 12 10.1 RYR2 KCNH2
4 right bundle branch block 10.1 SCN5A KCNH2
5 cardiomyopathy, dilated, 1b 10.1 TTN SCN5A
6 long qt syndrome 12 10.1 SCN5A KCNQ1 KCNH2
7 long qt syndrome 10 10.1 SCN5A KCNQ1 KCNH2
8 supravalvular aortic stenosis 10.1 SCN5A KCNH2
9 familial isolated arrhythmogenic ventricular dysplasia, left dominant form 10.0 TTN RYR2
10 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 10.0 TTN RYR2
11 long qt syndrome 11 10.0 KCNQ1 KCNJ2
12 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 10.0 TTN RYR2
13 cardiomyopathy, dilated, 1dd 10.0 TTN RYR2
14 peripartum cardiomyopathy 10.0 TTN SCN5A
15 familial periodic paralysis 10.0 SCN5A KCNJ2
16 arrhythmogenic right ventricular dysplasia, familial, 1 10.0 TTN RYR2
17 hyperkalemic periodic paralysis 10.0 SCN5A KCNJ2
18 brugada syndrome 1 10.0 SCN5A RYR2 KCNH2
19 progressive familial heart block 9.9 SCN5A KCNQ1
20 ventricular tachycardia, catecholaminergic polymorphic, 3 9.9 RYR2 KCNJ2
21 congenital structural myopathy 9.9 TTN RYR2
22 dopamine beta-hydroxylase deficiency 9.9 SLC6A2 DBH
23 familial isolated dilated cardiomyopathy 9.9 TTN SCN5A ACTN2
24 long qt syndrome 9 9.8 SCN5A KCNQ1 KCNJ2
25 familial short qt syndrome 9.8 KCNQ1 KCNJ2 KCNH2
26 oppositional defiant disorder 9.8 SLC6A2 DBH
27 diastolic heart failure 9.8 TTN NPPA
28 atrial heart septal defect 9.8 TTN SCN5A NPPA
29 cardiac conduction defect 9.8 SCN5A RYR2 KCNQ1 KCNH2
30 ventricular fibrillation, paroxysmal familial, 1 9.8 SCN5A RYR2 KCNQ1 KCNH2
31 sudden infant death syndrome 9.7 SCN5A RYR2 KCNQ1 KCNH2
32 third-degree atrioventricular block 9.7 TTN SCN5A KCNJ2
33 pure autonomic failure 9.7 NPPA DBH
34 familial long qt syndrome 9.6 SCN5A KCNQ1 KCNJ2 KCNH2
35 long qt syndrome 6 9.6 SCN5A KCNQ1 KCNJ2 KCNH2
36 long qt syndrome 13 9.6 SCN5A KCNQ1 KCNJ2 KCNH2
37 brugada syndrome 4 9.6 SCN5A KCNQ1 KCNJ2 KCNH2
38 jervell and lange-nielsen syndrome 1 9.6 SCN5A KCNQ1 KCNJ2 KCNH2
39 wolff-parkinson-white syndrome 9.6 SCN5A KCNQ1 KCNJ2 KCNH2
40 hypokalemic periodic paralysis, type 1 9.6 SCN5A KCNJ2
41 neuromuscular disease 9.6 TTN SCN5A ACTN2
42 coronary artery anomaly 9.5 SCN5A RYR2 NPPA KCNH2
43 hypertrophic cardiomyopathy 9.5 TTN SCN5A RYR2 ACTN2
44 muscular disease 9.5 TTN SCN5A RYR2 ACTN2
45 atrial standstill 1 9.4 TTN SCN5A RYR2 NPPA
46 atrioventricular block 9.4 TTN SCN5A RYR2 KCNQ1 KCNH2
47 cardiac arrest 9.3 TTN SCN5A RYR2 KCNQ1 KCNH2
48 sick sinus syndrome 9.3 TTN SCN5A NPPA KCNJ2
49 long qt syndrome 5 9.3 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2
50 sinoatrial node disease 9.3 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2

Graphical network of the top 20 diseases related to Syncope:



Diseases related to Syncope

Symptoms & Phenotypes for Syncope

MGI Mouse Phenotypes related to Syncope:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.81 DBH KCNH2 KCNJ2 KCNQ1 NPPA RYR2
2 growth/size/body region MP:0005378 9.56 DBH KCNH2 KCNJ2 KCNQ1 RYR2 SCN5A
3 muscle MP:0005369 9.17 KCNH2 KCNJ2 KCNQ1 NPPA RYR2 SCN5A

Drugs & Therapeutics for Syncope

Drugs for Syncope (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 308)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
3
Amlodipine Approved Phase 4 88150-42-9 2162
4
Losartan Approved Phase 4 114798-26-4 3961
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Bisoprolol Approved Phase 4 66722-44-9 2405
7
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
8
Interferon beta-1b Approved Phase 4 145155-23-3
9
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
14
Cefpirome Approved Phase 4 84957-29-9 5479539
15
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
16
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
17
Ramipril Approved Phase 4 87333-19-5 5362129
18
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
19
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
20
Ticagrelor Approved Phase 4 274693-27-5 9871419
21
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
22
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
23
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
24
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
25
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
26
Midodrine Approved Phase 4 42794-76-3, 133163-28-7 4195
27
Silodosin Approved Phase 4 160970-54-7
28
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
29
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
30
Procainamide Approved Phase 4 51-06-9 4913
31 Adrenergic Agonists Phase 4
32 Natriuretic Agents Phase 4
33 Dopamine Agents Phase 4
34 Antiparkinson Agents Phase 4
35 diuretics Phase 4
36 Protective Agents Phase 4
37 Hormones Phase 4
38 Sodium Chloride Symporter Inhibitors Phase 4
39 calcium channel blockers Phase 4
40 Contraceptive Agents Phase 4
41 (T,G)-A-L Phase 4
42 Fingolimod Hydrochloride Phase 4
43 Interferon-beta Phase 4
44 interferons Phase 4
45
Glatiramer Acetate Phase 4 147245-92-9 3081884
46 Adrenergic alpha-2 Receptor Agonists Phase 4
47 Estradiol 17 beta-cypionate Phase 4
48 Norgestimate, ethinyl estradiol drug combination Phase 4
49 Contraceptives, Oral, Combined Phase 4
50 Contraceptives, Oral Phase 4

Interventional clinical trials:

(show top 50) (show all 365)
# Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope Unknown status NCT01621464 Phase 4
2 Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
3 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Pacemaker Therapy for Patients With Asystolic Neurally-mediated Syncope Completed NCT00359203 Phase 4
4 A Randomized Clinical Trial of Fludrocortisone for Vasovagal Syncope: The Second Prevention of Syncope Trial (POST II) Completed NCT00118482 Phase 4 fludrocortisone acetate
5 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
6 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
7 Propranolol for Syncope With Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
8 The COMPAriSon of Systolic Blood Pressure Variability and Central Blood Pressure of Calcium Channel Blocker (Amlodipine) in Comparison With Angiotensin Receptor Blocker (Losartan) in Patients With Essential Hypertension Completed NCT01964079 Phase 4 Amlodipine;Losartan
9 Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM) Completed NCT01074307 Phase 4 Low Dose Bisoprolol;High Dose Bisoprolol
10 A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS) Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
11 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
12 Post Marketing Surveillance Study for LDL Apheresis Using H.E.L.P. Therapy Completed NCT00916643 Phase 4
13 Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease Completed NCT02525081 Phase 4 Ramipril (ACE-inhibitor);placebo
14 Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
15 Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease Completed NCT02383771 Phase 4 Ticagrelor;Aspirin + Ticagrelor;Control;Aspirin + Ticagrelor
16 An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose Completed NCT00344994 Phase 4 pramipexole
17 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
18 Effect of Pacemaker With Closed Loop Sensor on Quality of Life and Recurrence of Syncope in Patients With Neuromodulated Syncope Refractory to Medical Treatment: Randomized Double-blind Clinical Trial Recruiting NCT03876652 Phase 4
19 Effect of Pre-medication in Pain Measures on Office Hysteroscopy - Randomized Clinical Trial Recruiting NCT03506763 Phase 4 Placebo Oral + Placebo Oral;Diclofenac oral + Placebo Oral;Diclofenac oral + scopolamina oral
20 Randomized Evaluation of Beta Blocker and Angiotensin Converting Enzyme Inhibitor (ACEI) /Angiotensin Receptor Blocker (ARB) Treatment in MINOCA Patients. Recruiting NCT03686696 Phase 4 Beta blocker;ACEI;ARB
21 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
22 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4) Active, not recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
23 Comparison of Intravenous Amiodarone Versus Intravenous Procainamide for the Acute Treatment of Regular and Haemodynamically Well Tolerated Wide QRS Tachycardia (Probably of Ventricular Origen). The PROCAMIO Multicenter Study Terminated NCT00383799 Phase 4 iv Amiodarone;iv Procainamide
24 Comparison of Silodosin vs. Tamsulosin on Spontaneous Passage of Acutely Obstructing Ureteral Calculi in Medical Expulsive Therapy Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
25 Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo Unknown status NCT02071459 Phase 2, Phase 3 L-Threo DOPS;placebo
26 Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome Unknown status NCT02823080 Phase 2, Phase 3 Cetrorelix
27 Randomized, Double-Blinded, Oseltamivir-and-Placebo-Controlled Clinical Study About Lingdancao Granules in the Treatment of Seasonal Influenza Unknown status NCT02662426 Phase 3 Lingdancao granules;analogous oseltamivir phosphate capsule;Oseltamivir phosphate capsule;analogous Lingdancao granules
28 Randomized Controlled Trial on Discontinuation of Vasoactive Drugs in Patients With Hypotensive Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
29 Comparison of Ivabradine and Beta-blockers Administration in the Treatment of Inappropriate Sinus Tachycardia Completed NCT01657136 Phase 3 Ivabradine;Beta blocker
30 CSP #563 - Prazosin and Combat Trauma PTSD (PACT) Completed NCT00532493 Phase 3 prazosin
31 Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed NCT00000464 Phase 3 amiodarone;imipramine;mexiletine;procainamide;propafenone;quinidine;sotalol
32 Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14) Completed NCT01863186 Phase 3 Lofexidine HCl;Placebo;Open Label Lofexidine HCL
33 An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension Completed NCT00738062 Phase 3 Droxidopa;Placebo
34 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00782340 Phase 3 Placebo;Droxidopa
35 Antiarrhythmics Versus Implantable Defibrillators (AVID) Completed NCT00000531 Phase 3 amiodarone amiodarone;sotalol
36 A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
37 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00633880 Phase 3 Placebo;Droxidopa
38 Comprehensive Approach to Lower Measured Blood Pressure (CALM-BP) - Results From a Randomized Controlled Trial Completed NCT00409149 Phase 3
39 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
40 Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
41 Liposomal Bupivacaine To Control Post-Operative Pain Following Buccal Mucosal Graft Harvesting Active, not recruiting NCT03720223 Phase 3 Liposomal Bupivacaine
42 A Double Blind Randomized Controlled Crossover Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe Postural Orthostatic Tachycardia Syndrome Not yet recruiting NCT03365414 Phase 3 Normal Saline 0.9% Infusion Solution Bag
43 Intensive Blood Pressure Intervention in Stroke (IBIS) Trial Not yet recruiting NCT03585595 Phase 3
44 Benefit of Controlled Rehydration in Unexplained Syncope Terminated NCT00143754 Phase 3
45 BRD 06/2-D (Quidam) "Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator" Terminated NCT00927732 Phase 3 hydroquinidine;placebo (sugar)
46 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL Withdrawn NCT01560091 Phase 3 silodosin;Tamsulosin
47 Second Study on Cardio-neuromodulation in Humans Unknown status NCT02954666 Phase 2
48 ECG Device for Long QT Syndrome Screening in Newborns Unknown status NCT02412709 Phase 2
49 A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST 6 Completed NCT02500732 Phase 2 Atomoxetine;Placebo
50 A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope (POST 6) Completed NCT02874937 Phase 2 Atomoxetine;Matching Placebo

Search NIH Clinical Center for Syncope

Genetic Tests for Syncope

Genetic tests related to Syncope:

# Genetic test Affiliating Genes
1 Syncope 29

Anatomical Context for Syncope

MalaCards organs/tissues related to Syncope:

40
Testes, Heart, Brain, Skin, Lung, Prostate, Liver

Publications for Syncope

Articles related to Syncope:

(show top 50) (show all 15545)
# Title Authors PMID Year
1
Severe impaired blood pressure control caused by baroreflex failure as a late sequela of neck irradiation. 61
31764585 2020
2
Ventricular conduction delay as marker of risk in Brugada Syndrome. Results from the analysis of clinical and electrocardiographic features of a large cohort of patients. 61
31771792 2020
3
How to Prescribe Drugs With an Identified Proarrhythmic Liability. 61
31743455 2020
4
Screening Pediatric Patients in New-Onset Syncope (SPINS) Study. 61
31709814 2020
5
Web Exclusive. Annals Graphic Medicine - Dr. Mom: Syncope. 61
32016337 2020
6
Abolish the Tilt Table Test for the Workup of Syncope! 61
32011926 2020
7
Micturition Syncope: A Personal Experience With a Novel Explanation. 61
31959316 2020
8
Left Atrial "Pinball" Thrombus Causing Recurrent Syncope. 61
32005792 2020
9
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. 61
31818699 2020
10
Effect of Pregnancy in Arrhythmogenic Right Ventricular Cardiomyopathy. 61
31836129 2020
11
Family history of associated disorders in patients with postural tachycardia syndrome. 61
32008600 2020
12
Medium-term results of cardioneuroablation for clinical bradyarrhythmias and vasovagal syncope: effects on QT interval and heart rate. 61
32034611 2020
13
Pacing in vasovagal syncope: physiology, pacemaker sensors and recent clinical trials. Precise patient selection and measurable benefit. 61
32036025 2020
14
Impact of dual-chamber pacing with closed loop stimulation on quality of life in patients with recurrent reflex vasovagal syncope: results of the SPAIN study. 61
31713631 2020
15
Molecular genetic framework underlying pulmonary arterial hypertension. 61
31406341 2020
16
Postural Tachycardia Syndrome and Neurally Mediated Syncope. 61
31996624 2020
17
The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. 61
31864099 2020
18
Electrocardiogram Characteristics and Arrhythmic Events during Fever in Patients with Fever-Induced Brugada Syndrome. 61
32015236 2020
19
Chest pain in Brugada syndrome prevalence, correlations and prognosis role. 61
32031268 2020
20
SCN8A heterozygous variants are associated with anoxic-epileptic seizures. 61
32040247 2020
21
Parameters of Right Ventricular Function Reveal Ventricular-Vascular Mismatch as Determined by Right Ventricular Stroke Work versus Pulmonary Vascular Resistance in Children with Pulmonary Hypertension. 61
31836268 2020
22
Anomalous origin of the coronary artery coursing between the great vessels presenting with a cardiovascular event (J-CONOMALY Registry). 61
31185091 2020
23
Drug-induced proarrhythmia: Discussion and considerations for clinical practice. 61
32015278 2020
24
Drug-induced proarrhythmia: Discussion and considerations for clinical practice. 61
31990841 2020
25
Risk Stratification of Older Adults Who Present to the Emergency Department With Syncope: The FAINT Score. 61
31668571 2020
26
Acute Myocarditis in Children: An Overview of Treatment and Recent Patents. 61
32013855 2020
27
Staged Combined Endovascular and Open Surgical Approach in a Patient with Takayasu's Arteritis. 61
31629850 2020
28
Emergency department management of eating disorder complications in pediatric patients 61
31978295 2020
29
Cardiac Imaging in the Athlete: Shrinking the "Gray Zone". 61
32016641 2020
30
Differential diagnosis of vasovagal syncope and postural tachycardia syndrome in children. 61
32020440 2020
31
Convulsive Syncope Masquerading as Seizure After an Epidural Blood Patch. 61
31910260 2020
32
Ictal vasodepressive syncope in temporal lobe epilepsy. 61
31765979 2020
33
Epilepsy in the elderly: Unique challenges in an increasingly prevalent population. 61
31816480 2020
34
Memantine Induces Reflex Syncope in Elderly Patients With Dementia: Results From the Syncope and Dementia Study (SYD-Study). 61
30872082 2020
35
Effects of Alcohol Administered With Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study. 61
31735618 2020
36
Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany. 61
32003157 2020
37
Plasma-lactate levels in simulated seizures - An observational study. 61
32004878 2020
38
Choosing wisely in emergency medicine: Early results and insights from the ACEP emergency quality network (E-QUAL). 61
32014376 2020
39
To STOPP or to START? Potentially inappropriate prescribing in older patients with falls and syncope. 61
31787149 2020
40
The Wide-Ranging Spectrum of Cough-Induced Complications and Patient Harm. 61
32007456 2020
41
Sources of Variability in Pediatric Head Computed Tomography Use Among Emergency Departments in New Jersey. 61
31895199 2020
42
Syncope in Malaysian populations. 61
31925588 2020
43
Syncope in a young woman. 61
31974258 2020
44
Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study. 61
31929538 2020
45
Transient high-degree right bundle branch block masking the type 1 Brugada ECG pattern associated with possible transient early repolarization syndrome. 61
31343106 2020
46
Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension. 61
31941943 2020
47
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. 61
31983465 2020
48
When Sinus Tachycardia Becomes Too Much: Negative Effects of Excessive Upright Tachycardia on Cardiac Output in Vasovagal Syncope, Postural Tachycardia Syndrome, and Inappropriate Sinus Tachycardia. 61
31941353 2020
49
Comparison of trinitroglycerin and adenosine as provocative agents for head-up tilt test in patients with unexplained syncope: a semi-crossover randomized clinical trial with prospective follow-up. 61
31907833 2020
50
Predictive Accuracy of Electrocardiographic Monitoring of Patients With Syncope in the Emergency Department: The SyMoNE Multicenter Study. 61
31854141 2020

Variations for Syncope

ClinVar genetic disease variations for Syncope:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SCN5A NM_198056.2(SCN5A):c.1255C>T (p.Gln419Ter)SNV Likely pathogenic 374130 rs1057518916 3:38647525-38647525 3:38606034-38606034
2 ACTL6A NM_004301.5(ACTL6A):c.1129C>T (p.Arg377Trp)SNV Likely pathogenic 549661 rs868064163 3:179304340-179304340 3:179586552-179586552
3 ACTN2 NM_001103.3(ACTN2):c.1040C>T (p.Thr347Met)SNV Conflicting interpretations of pathogenicity 178985 rs727504590 1:236902765-236902765 1:236739465-236739465
4 MEFV NM_000243.2(MEFV):c.2084A>G (p.Lys695Arg)SNV Conflicting interpretations of pathogenicity 2547 rs104895094 16:3293403-3293403 16:3243403-3243403
5 KCNE3 , LIPT2 NM_005472.4(KCNE3):c.248G>A (p.Arg83His)SNV Conflicting interpretations of pathogenicity 5541 rs17215437 11:74168361-74168361 11:74457316-74457316
6 TTN NM_001267550.2(TTN):c.11311+4088A>GSNV Conflicting interpretations of pathogenicity 47753 rs142304137 2:179613763-179613763 2:178749036-178749036
7 RYR2 NM_001035.3(RYR2):c.2026G>A (p.Glu676Lys)SNV Uncertain significance 689574 1:237659875-237659875 1:237496575-237496575

Expression for Syncope

Search GEO for disease gene expression data for Syncope.

Pathways for Syncope

Pathways related to Syncope according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 KCNQ1 KCNJ2 KCNH2 ACTN2
2
Show member pathways
12.06 SCN5A RYR2 NPPA KCNQ1
3 11.99 KCNQ1 KCNJ2 KCNH2
4
Show member pathways
11.95 TTN SCN5A RYR2 NPPA KCNQ1 KCNJ2
5
Show member pathways
11.71 KCNQ1 KCNJ2 KCNH2
6 11.67 SCN5A RYR2 KCNQ1 KCNH2
7
Show member pathways
11.11 SLC6A2 DBH
8 11.1 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2
9 10.79 SLC6A2 DBH
10
Show member pathways
10.77 SLC6A2 DBH
11 10.6 KCNQ1 KCNJ2

GO Terms for Syncope

Cellular components related to Syncope according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intercalated disc GO:0014704 9.37 SCN5A KCNJ2
2 voltage-gated potassium channel complex GO:0008076 9.33 KCNQ1 KCNJ2 KCNH2
3 T-tubule GO:0030315 9.32 SCN5A KCNJ2
4 smooth endoplasmic reticulum GO:0005790 9.26 RYR2 KCNJ2
5 sarcomere GO:0030017 9.13 TTN RYR2 ACTN2
6 Z disc GO:0030018 8.92 TTN SCN5A RYR2 ACTN2

Biological processes related to Syncope according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.93 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2
2 transmembrane transport GO:0055085 9.92 SLC6A2 SCN5A RYR2 KCNQ1 KCNH2
3 potassium ion transport GO:0006813 9.81 KCNQ1 KCNJ2 KCNH2
4 potassium ion transmembrane transport GO:0071805 9.81 KCNQ1 KCNJ2 KCNH2
5 regulation of ion transmembrane transport GO:0034765 9.81 SCN5A KCNQ1 KCNJ2 KCNH2
6 positive regulation of heart rate GO:0010460 9.67 RYR2 NPPA KCNQ1
7 potassium ion import across plasma membrane GO:1990573 9.66 KCNJ2 KCNH2
8 sarcomere organization GO:0045214 9.65 TTN ACTN2
9 muscle filament sliding GO:0030049 9.65 TTN ACTN2
10 regulation of heart rate GO:0002027 9.65 SCN5A RYR2
11 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.65 SCN5A KCNQ1 KCNH2
12 response to pain GO:0048265 9.64 SLC6A2 DBH
13 membrane depolarization during action potential GO:0086010 9.63 SCN5A KCNH2
14 positive regulation of potassium ion transmembrane transport GO:1901381 9.63 KCNQ1 KCNJ2 KCNH2
15 cardiac muscle cell action potential involved in contraction GO:0086002 9.62 SCN5A KCNJ2
16 response to muscle stretch GO:0035994 9.62 RYR2 NPPA
17 cardiac conduction GO:0061337 9.62 SCN5A KCNQ1 KCNJ2 KCNH2
18 potassium ion export across plasma membrane GO:0097623 9.61 KCNQ1 KCNH2
19 regulation of cardiac muscle cell contraction GO:0086004 9.61 SCN5A KCNJ2
20 regulation of membrane repolarization GO:0060306 9.61 KCNQ1 KCNJ2 KCNH2
21 cellular response to epinephrine stimulus GO:0071872 9.6 RYR2 KCNQ1
22 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.59 KCNQ1 KCNH2
23 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.58 SCN5A KCNJ2
24 membrane repolarization GO:0086009 9.58 KCNQ1 KCNH2
25 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.58 KCNQ1 KCNJ2 KCNH2
26 positive regulation of cardiac muscle contraction GO:0060452 9.57 NPPA KCNQ1
27 cardiac muscle hypertrophy GO:0003300 9.56 TTN RYR2
28 atrial cardiac muscle cell action potential GO:0086014 9.55 SCN5A KCNQ1
29 membrane repolarization during action potential GO:0086011 9.54 KCNQ1 KCNJ2 KCNH2
30 regulation of heart rate by cardiac conduction GO:0086091 9.46 SCN5A KCNQ1 KCNJ2 KCNH2
31 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.43 SCN5A NPPA KCNQ1
32 ventricular cardiac muscle cell action potential GO:0086005 9.26 SCN5A RYR2 KCNQ1 KCNH2
33 cardiac muscle contraction GO:0060048 9.02 TTN SCN5A RYR2 KCNQ1 KCNH2

Molecular functions related to Syncope according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 TTN RYR2 KCNJ2 KCNH2 ACTN2
2 ion channel activity GO:0005216 9.63 SCN5A RYR2 KCNH2
3 calmodulin binding GO:0005516 9.56 TTN SCN5A RYR2 KCNQ1
4 structural constituent of muscle GO:0008307 9.54 TTN ACTN2
5 phosphatidylinositol-4,5-bisphosphate binding GO:0005546 9.54 KCNQ1 KCNJ2 ACTN2
6 delayed rectifier potassium channel activity GO:0005251 9.52 KCNQ1 KCNH2
7 scaffold protein binding GO:0097110 9.5 SCN5A KCNQ1 KCNH2
8 protein kinase A regulatory subunit binding GO:0034237 9.49 RYR2 KCNQ1
9 inward rectifier potassium channel activity GO:0005242 9.48 KCNJ2 KCNH2
10 ion channel binding GO:0044325 9.46 SCN5A RYR2 KCNQ1 ACTN2
11 protein kinase A catalytic subunit binding GO:0034236 9.43 RYR2 KCNQ1
12 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.4 KCNQ1 KCNH2
13 voltage-gated ion channel activity GO:0005244 9.26 SCN5A KCNQ1 KCNJ2 KCNH2
14 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 8.8 KCNQ1 KCNJ2 KCNH2

Sources for Syncope

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....